DiagnostykaFRA:7JS +1.17%19 Return-on-Tangible-Asset is 22.31% as of Mar. 2026, which is 15% above its 10-year median of 19.37. GuruFocus rates FRA:7JS with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 215 Medical Diagnostics & Research companies, Diagnostyka ranks better than 93.02% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Diagnostyka's annualizedNet Income for the quarter that ended in Mar. 2026 was €76.4 Mil. Diagnostyka's average total tangible assets for the quarter that ended in Mar. 2026 was €342.5 Mil. Therefore, Diagnostyka's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 22.31%.
The historical rank and industry rank for Diagnostyka's Return-on-Tangible-Asset or its related term are showing as below:
FRA:7JS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 12.68 Med: 19.37 Max: 55.31
Current: 19.21
During the past 5 years, Diagnostyka's highest Return-on-Tangible-Asset was 55.31%. The lowest was 12.68%. And the median was 19.37%.
FRA:7JS's Return-on-Tangible-Asset is ranked better than 93.02% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs FRA:7JS: 19.21
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Diagnostyka Return-on-Tangible-Asset Related Terms
Diagnostyka Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Diagnostyka's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7JS vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Diagnostyka's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Diagnostyka's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 22.31% mean?
Diagnostyka (FRA:7JS) has a Return-on-Tangible-Asset of 22.31% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Diagnostyka and its competitors. This is 15% above median its historical median of 19.37. Over the past decade, Diagnostyka's Return-on-Tangible-Asset has ranged from 12.68 to 55.31. According to the industry distribution chart, Diagnostyka ranks #15 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 7%.
Is Diagnostyka's Return-on-Tangible-Asset too high?
Diagnostyka's current Return-on-Tangible-Asset of 22.31% is 15% above median its 10-year median of 19.37. Over the past 10 years, this metric has ranged from a low of 12.68 to a high of 55.31. Based on the distribution chart, Diagnostyka ranks #15 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnostyka has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #15 out of 215 companies for Return-on-Tangible-Asset. This places Diagnostyka in the top 7% of its industry — outperforming the majority of peers. Historically, Diagnostyka's own Return-on-Tangible-Asset has ranged from 12.68 to 55.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Diagnostyka and its competitors. Diagnostyka's current Return-on-Tangible-Asset is 22.31%, which is 15% above median its own 10-year median of 19.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current Return-on-Tangible-Asset of 22.31%. The current Return-on-Tangible-Asset is 22.31%, which is 15% above median its 10-year median of 19.37. Diagnostyka's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current Return-on-Tangible-Asset is 22.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
19GF Score
Get the complete analysis for FRA:7JS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
